Advances in pediatric asthma in 2011: Moving forward - 24/12/11
Abstract |
Last year’s “Advances in pediatric asthma” concluded with the following statement: “Perhaps new directions in personalized medicine and improved health care access and communication will help maintain steady progress in alleviating the burden of this disease in children, especially young children.” This year’s summary will focus on recent advances in pediatric asthma that show significant accomplishments in reducing asthma morbidity and mortality over the last 10 years and discuss some pathways to further reduce asthma burden, as indicated in Journal of Allergy and Clinical Immunology publications in 2011. Some of the recent reports continue to shed light on methods to improve asthma management through steps to reduce asthma exacerbations, identify features of the disease in early childhood, alter asthma progression, intervene with nutrition, and more effectively implement the asthma guidelines. As new information evolves, it is also time to consider a revision of the asthma guidelines based on key studies that affect our management of the disease since the last revision in 2007. Now is also the time to use information recorded in electronic medical records to develop innovative disease management plans that will track asthma over time and enable timely decisions on interventions to maintain control that can lead to disease remission and prevention.
Le texte complet de cet article est disponible en PDF.Key words : Airway remodeling, asthma, asthma control, asthma exacerbations, asthma impairment, asthma risk, asthma severity, early intervention in asthma, biomarkers, environment, genetics, inhaled corticosteroids, leukotriene receptor antagonists, long-acting β-adrenergic agonists, omalizumab, personalized medicine, severe asthma, therapeutics, tiotropium
Abbreviations used : COPD, Feno, ICS, LABA, NAEPP, NHLBI
Plan
Supported in part by Public Health Services Research Grants HL-64288, HL-51834, AI-90052, HL-75416, HL-87811, ES-18181, and HL-98075 and the Colorado Cancer, Cardiovascular, and Pulmonary Disease Program. Supported in part by Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health (NIH) and the National Center for Research Resources (NCRR). |
|
Disclosure of potential conflict of interest: S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health; the National Heart, Lung, and Blood Institute; the National Institute for Allergy and Infectious Diseases; the National Institute for Environmental Health Sciences; the US Environmental Protection Agency; and GlaxoSmithKline. |
Vol 129 - N° 1
P. 60-68 - janvier 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?